T-Cell Lymphoma: Q&A
Precision Medicine for T-Cell Lymphomas: Expert Answers to Your Questions

Released: January 31, 2022

Expiration: January 30, 2023

Francine Foss
Francine Foss, MD
Steven M. Horwitz
Steven M. Horwitz, MD
Barbara Pro
Barbara Pro, MD

Activity

Progress
1
Course Completed

In this episode, Steven M. Horwitz, MD; Francine Foss, MD; and Barbara Pro, MD, answer questions from an audience of healthcare professionals on topics related to the management of patients with T-cell lymphomas including:

  • Threshold of CD30 positivity useful to inform brentuximab vedotin use in patients with CTCL and PTCL
  • Managing relapsed mycosis fungoides after allogeneic SCT
  • Experience with ALK inhibition in ALCL with central nervous system metastases
  • Managing refractory pruritus in CTCL
  • Role of PI3K inhibitors in frontline and relapsed/refractory PTCL
  • When to consider SCT in CTCL cycling through monotherapies